We are excited to announce that Biocytogen will be heading to Life Science Innovation Northwest 2026, hosted by Life Science Washington. As the Pacific Northwest’s largest annual life science conference, the event will bring together over 700 innovators for two days of collaborative learning and elevated networking. Come meet our team, at booth #202, and learn how Biocytogen’s cutting-edge platforms are shaping the future of drug development!
What is Life Science Washington?
Life Science Washington is an independent 501(c)(6) nonprofit trade organization, connecting and driving the science ecosystem of Washington state. They are an advocate of public policy and private investment, working towards the goal of growing the economic sector and creating healthier communities.
Event Overview
Date: April 21st - 22nd, 2026
Venue: Seattle Convention Center, 705 Pike St, Seattle, WA 98101
Event Schedule
For more information, please refer to the program schedule.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Seattle, WA!
